Cancer clinical trial database.
Every new trial and trial result from New in Oncology, our weekly research briefing, since the first issue on . Search by NCT number, drug, or cancer type.
Latest entries
- New trial
Breast cancer
Phase II Adjuvant Trial: Evaluating Chemotherapy Omission in ER+/HER2– Breast Cancer
Yale University is investigating whether ribociclib combined with optimized endocrine therapy, minus adjuvant chemotherapy, improves treatment adherence and outcomes in moderate to high-anatomical risk, low-genomic…
NCT06953882 - New trial
Prostate cancer
Phase II Study: Sequential BATZEN and ZENZA Therapy in Metastatic CRPC
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins is testing whether an initial phase of testosterone plus ZEN-3694 (BATZEN) followed by dose-escalated ZEN-3694 with enzalutamide (ZENZA) can reduce tumor…
NCT06922318 - New trial
Prostate cancer
Phase II Trial: Evaluating Enhertu in HER2+ mCRPC
Washington D.C. Veterans Affairs Medical Center is assessing the efficacy and safety of fam-trastuzumab deruxtecan-nxki (Enhertu) in HER2-positive metastatic castration-resistant prostate cancer patients who have…
NCT06610825 - New trial
Prostate cancer
Phase III Study: Adjuvant Saruparib with RT + ADT in BRCA-Mutant High-Risk Prostate Cancer
AstraZeneca is investigating whether adding the PARP1 inhibitor saruparib (AZD5305) to standard radiation therapy and androgen deprivation therapy—with or without abiraterone—improves metastases-free survival in…
NCT06952803 - New trial
Head and neck cancer
Pilot Evaluating 111In-Panitumumab for Nodal Staging in Head and Neck Cancer
Stanford University is conducting a pilot diagnostic study to assess the safety of 111In-panitumumab—an EGFR-directed SPECT imaging agent—for nodal staging in patients with head and neck squamous cell carcinoma. The…
NCT04840472 - New trial
Head and neck cancer
Circulating Tumor HPV DNA Driven Adjuvant Treatment Deintensification After Transoral Surgery for HPV+ OPSCC
Indiana University is conducting this Phase II trial to assess whether postoperative ctHPVDNA levels can guide adjuvant therapy deintensification after transoral surgery and neck dissection in HPV+ oropharyngeal…
NCT06915038 - New trial
Head and neck cancer
Pilot Window Study: Imatinib Combined with Cetuximab in Head and Neck Squamous Cell Carcinomas
University of Wisconsin – Madison is investigating whether tumor AXL levels correlate with treatment response to imatinib mesilate combined with cetuximab in patients with head and neck squamous cell carcinoma.…
NCT05816785 - New trial
Bladder and urothelial cancer
Phase II Study: 5-ALA–Enhanced Fluorescence for Upper Tract Urothelial Cancer Detection
Henry Ford Health System is evaluating whether a single oral dose of 5-ALA given 2–4 hours preoperatively improves the visibility of upper tract urothelial tumors via blue light fluorescence during ureteroscopic…
NCT06948552 - New trial
Sarcoma and GIST
Expanded Access: Bezuclastinib with Sunitinib in Advanced GIST
Cogent Biosciences, Inc. is offering investigational bezuclastinib in combination with sunitinib to patients with locally advanced, unresectable, or metastatic gastrointestinal stromal tumors who have no comparable…
NCT06948955 - New trial
Neuroendocrine and adrenal tumors
Zanzalintinib Maintenance in High Grade Neuroendocrine Neoplasms
Washington University School of Medicine is evaluating zanzalintinib as a maintenance therapy following initial chemotherapy to extend progression-free survival in patients with high-grade neuroendocrine neoplasms.…
NCT06926634 - New trial
Multiple myeloma
Phase II Study of Elranatamab as Maintenance Therapy Post Cilta-cel in High Risk Relapsed Myeloma
H. Lee Moffitt Cancer Center and Research Institute is evaluating whether maintenance therapy with elranatamab, initiated 3–6 months after cilta-cel infusion, can extend progression-free survival in patients with…
NCT06947083 - New trial
Small cell lung cancer
Phase 1 Dose Escalation Study of ZG006 in Small Cell Lung Cancer
Suzhou Zelgen Biopharmaceuticals is evaluating ZG006—a DLL3 and CD3 directed bispecific mAb—in small cell lung cancer patients intolerant to standard treatment, using a 3+3 dose escalation design to determine the…
NCT06592638 - New trial
Lymphoma
PROMOTE-FL: Pirtobrutinib and Mosunetuzumab to Enhance Treatment Efficacy for Patients With Relapsed/Refractory Follicular Lymphoma
University of Washington is testing the combination of pirtobrutinib, a BTK inhibitor, and mosunetuzumab, a bispecific antibody targeting CD20 and CD3, in relapsed/refractory grade 1-3a follicular lymphoma patients.…
NCT06948786 - New trial
Lymphoma
Phase 2 Study: Epcoritamab and Loncastuximab Tesirine in Relapsed/Refractory Large B-cell Lymphoma
University of Miami is investigating whether the combination of epcoritamab and loncastuximab tesirine can safely and effectively reduce lymphoma cells in patients with relapsed/refractory large B-cell lymphoma.…
NCT06919939 - New trial
Lymphoma
Phase 1 Study: Evaluating UF-KURE19 CAR-T Cells for Relapsed/Refractory B Cell NHL
Case Western is assessing the safety and manufacturing feasibility of UF-KURE19—a CD19-targeted CAR-T cell therapy modified via a shortened lentiviral process—in patients with relapsed non-Hodgkin lymphoma (with or…
NCT05400109 - New trial
Liver and bile duct cancer
Phase III Study: Rilvegostomig Combinations in First-line Advanced HCC
AstraZeneca is evaluating whether rilvegostomig combined with bevacizumab—with or without tremelimumab—can improve outcomes compared to atezolizumab plus bevacizumab in patients with unresectable advanced…
NCT06921785 - New trial
Liver and bile duct cancer
Phase 1b/2 Study: Ivosidenib, Durvalumab, & Gemcitabine/Cisplatin in IDH1-Mutant Cholangiocarcinoma
Institut de Recherches Internationales Servier is evaluating the safety, tolerability, and preliminary clinical activity of a combination therapy—ivosidenib with durvalumab and gemcitabine/cisplatin—as first-line…
NCT06501625 - New trial
Pancreatic cancer
Phase Ib Study: PTM-101 as an Adjunct to Neoadjuvant Therapy in Advanced PDAC
PanTher Therapeutics is evaluating PTM-101—a PLZ4-coated paclitaxel-loaded micelle nanoparticle—in combination with standard neoadjuvant chemotherapy in treatment-naïve patients with borderline resectable or locally…
NCT06673017 - New trial
Melanoma
Phase 2 Trial: Adjuvant Quisinostat in High-Risk Uveal Melanoma
University of Miami is evaluating whether quisinostat, an HDAC inhibitor, can prevent metastatic spread in high-risk uveal melanoma when used as adjuvant therapy. Participants receive up to 17 cycles over 51 weeks…
NCT06932757 - New trial
Kidney cancer
Randomized Phase II Trial of XL092 in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCC
Columbia University Medical Center is testing XL092 alone versus XL092 combined with nivolumab in patients with advanced clear cell RCC who have progressed on adjuvant anti-PD-1/PD-L1 therapy, with treatment given in…
NCT06863311 - New trial
Colorectal cancer
Phase II Pilot Study: Y-90, Capecitabine & Atezolizumab in Unresectable CRC Liver Metastases (METEORITE)
Brown University is leading a single-arm phase II trial evaluating yttrium-90 radioembolization combined with capecitabine and atezolizumab for patients with oligometastatic colorectal cancer liver metastases…
NCT06555133 - New trial
Sarcoma and GIST
Phase 1/2 Study: ADCE-D01 in Advanced Soft Tissue Sarcoma
Adcendo ApS is evaluating ADCE-D01—a humanized anti-uPARAP antibody linked to a topoisomerase I inhibitor—to assess its safety, pharmacokinetics, and antitumor activity in patients with metastatic and/or unresectable…
NCT06797999 - New trial
Multiple solid tumors
Phase II Trial: DB-1311 Combinations in Advanced/Metastatic Solid Tumors
DualityBio Inc. is assessing the safety and efficacy of DB-1311 – a B7-H3-directed ADC – in combination with either BNT327 (a VEGFA-directed mAb) or DB-1305 (a HER2-directed ADC) across multiple advanced solid tumors…
NCT06953089 - New trial
Multiple solid tumors
Pilot Study: Proton SBRT for Complex Spinal Metastases
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins is evaluating proton stereotactic body radiotherapy for nonhematologic spinal metastases in patients with complex lesions that cannot be effectively treated…
NCT06895564 - New trial
Multiple solid tumors
First-in-Human Study: TYRA-430 in FGFR-Driven Advanced Cancers
Tyra Biosciences, Inc. is evaluating TYRA-430—a novel FGFR4 inhibitor—as monotherapy in a dose-escalation and expansion study in patients with advanced hepatocellular carcinoma and other solid tumors harboring…
NCT06915753 - New trial
Multiple solid tumors
Phase 1a/1b Study of PHST001 in Advanced Relapsed/Refractory Solid Tumors
Pheast Therapeutics is investigating PHST001 in an open-label, dose escalation and expansion trial to evaluate its safety, pharmacokinetics, pharmacodynamics, and antitumor activity, and to determine the recommended…
NCT06840886 - New trial
Multiple solid tumors
Phase III Trial: Pafolacianine for Localization of Pediatric Extracranial Solid Tumors
Mayo Clinic is evaluating pafolacianine—an IV-administered, folate receptor-targeted fluorescent imaging agent used with near infrared (NIR) imaging—to enhance the identification of cancerous lesions during standard…
NCT06915727 - New trial
Multiple solid tumors
Phase II Trial: Photon-VMAT Craniospinal Irradiation for Leptomeningeal Disease
City of Hope Medical Center is evaluating photon volumetric modulated arc therapy for craniospinal irradiation as a treatment for leptomeningeal disease secondary to breast cancer or NSCLC, with patients receiving…
NCT06910761 - New trial
Multiple solid tumors
Phase 1 Study: BGB-B455 in CLDN6-Positive Advanced Solid Tumors
BeiGene is investigating BGB-B455—a CLDN6-directed CD3 activator bispecific antibody—as monotherapy in patients with advanced or metastatic solid tumors with no standard care options. This open-label study includes a…
NCT06803680 - New trial
Multiple solid tumors
Phase 1 Trial of QTX3544 in KRAS G12V Advanced Solid Tumors
Quanta Therapeutics is evaluating QTX3544—a KRAS inhibitor—both as monotherapy and in combination with cetuximab in patients with advanced solid tumors harboring KRAS G12V mutations through dose escalation and…
NCT06715124
Looking for trials that fit a specific diagnosis? Read our guide on how to find a clinical trial, or subscribe to New in Oncology to get each issue by email.